In patients with a history of ASCVD and statin therapy, PCSK9 inhibitors significantly lowered plasma LDL-C levels and the risk of cardiovascular (CV) events (e.g., CV death, myocardial infarction, stroke) compared to the control group with only the standard therapy [126,127,128,129]. This evidence concerns the gene PCSK9 and stroke disorder.